The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.

@article{Youdim2001TheAD,
  title={The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.},
  author={Moussa B. H. Youdim and Akshay Wadia and William G. Tatton and Marta Weinstock},
  journal={Annals of the New York Academy of Sciences},
  year={2001},
  volume={939},
  pages={450-8}
}
The antiapoptotic and neuroprotective activity of irreversible monoamine oxidase (MAO) B inhibitor, rasagiline [R(+)-N-propargyl-1-aminioindan], its S-isomer (TVP1022) and TV 3219, a novel anti-Alzheimer cholinesterase-MAO inhibitor drug derived from rasagiline were examined in PC12 cells cultures and in vivo. We found that these drugs have potent antiapoptotic and neuroprotective activities in response to serum and NGF withdrawal in partially neuronally differentiated PC12 cells and prevent… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

The use of rasagiline in Parkinson's disease.

Journal of neural transmission. Supplementum • 2006
View 9 Excerpts
Highly Influenced

Rasagiline in Parkinson's disease.

International review of neurobiology • 2011
View 8 Excerpts
Highly Influenced

Rasagiline in treatment of Parkinson’s disease

Neuropsychiatric disease and treatment • 2008
View 4 Excerpts
Highly Influenced

Kinetics, mechanism, and inhibition of monoamine oxidase

Journal of Neural Transmission • 2018
View 1 Excerpt

Similar Papers

Loading similar papers…